BlackRock Investment Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

BlackRock Investment Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1.86M	Sell	293,567 -1,453	-0.5%	-$7.56K	﹤0.01%	2266
2016 Q3	$1.3M	Buy	295,020 +17,000	+6%	+$67.9K	﹤0.01%	2487
2016 Q2	$790K	Buy	278,020 +16,483	+6%	+$51.2K	﹤0.01%	2792
2016 Q1	$740K	Buy	261,537 +3,855	+1%	+$17.1K	﹤0.01%	2684
2015 Q4	$2.66M	Buy	257,682 +2	+0%	+$20	﹤0.01%	1880
2015 Q3	$2.94M	Sell	257,680 -20,717	-7%	-$276K	﹤0.01%	1763
2015 Q2	$4.16M	Buy	278,397 +51,262	+23%	+$583K	0.01%	1643
2015 Q1	$2.05M	Buy	227,135 +2,771	+1%	+$28.7K	﹤0.01%	2004
2014 Q4	$2.73M	Sell	224,364 -2,211	-1%	-$24.4K	﹤0.01%	1801
2014 Q3	$2.22M	Buy	226,575 +2,024	+0.9%	+$24.8K	﹤0.01%	1925
2014 Q2	$2.86M	Buy	+224,551	New	+$2.18M	﹤0.01%	1797

Other funds holding BCRX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Investment Management's BCRX Position: Q4 2016 in Review

BlackRock Investment Management reduced its BioCryst Pharmaceuticals (BCRX) stake by 0.49% in Q4 2016, selling an estimated $7.56K and leaving 293,567 shares worth $1.86M. The position accounts for ﹤0.01% of the portfolio, ranked #2266.

BlackRock Investment Management first reported a position in BCRX in Q2 2014 and has held it in 11 quarters since. The position peaked at $4.16M in Q2 2015. 112 funds tracked by Wall St. Rank hold BCRX as of Q4 2016.

BlackRock Investment Management held 293,567 shares of BioCryst Pharmaceuticals worth $1.86M as of Q4 2016.
BlackRock Investment Management sold 1,453 BioCryst Pharmaceuticals shares in Q4 2016, an estimated $7.56K.
BioCryst Pharmaceuticals made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #2266 holding.
BlackRock Investment Management first reported a position in BioCryst Pharmaceuticals in Q2 2014 and has held it in 11 quarters since.
BlackRock Investment Management's BioCryst Pharmaceuticals position peaked at $4.16M in Q2 2015.
112 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.